Pharmacodynamics and tolerability of L-654,066, a steroid 5 alpha-reductase inhibitor, in men
| Autor: | Oscar L. Laskin, Carol Meeter, Agnes Buntinx, Paul J. De Schepper, Anne Van Hecken, M Depre |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class Pharmacology Biology Placebo 5 Alpha-Reductase Inhibitor 5-alpha Reductase Inhibitors Double-Blind Method Reference Values Internal medicine medicine Humans Pharmacology (medical) Testosterone Dose-Response Relationship Drug Dihydrotestosterone Androgen Dose–response relationship Endocrinology Tolerability Pharmacodynamics Azasteroids medicine.drug |
| Zdroj: | Clinical pharmacology and therapeutics. 52(4) |
| ISSN: | 0009-9236 |
| Popis: | A four-period, two-panel single rising-dose study (0.1 to 100 mg) was conducted in healthy men to investigate the pharmacodynamics and tolerability of L-654,066, a steroid 5 alpha-reductase inhibitor. Within each panel, six subjects received L-654,066 and two subjects received placebo at each dose level; the placebo subjects changed between periods so that each subject received placebo once. Testosterone and dihydrotestosterone were measured in serum at 0, 4, 24, and 48 hours after each treatment. L-654,066 was associated with a significant reduction in serum dihydrotestosterone concentrations, which was maximal at 48 hours after dose. Forty-eight hours after treatment, mean percentage of inhibition was 24% and 39% for the 0.1 and 0.5 mg doses, respectively, and ranged from 50% to 65% at doses from 1 to 25 mg and from 70% to 75% at doses from 50 to 100 mg. Testosterone serum levels did not show any significant difference between the various treatments, including placebo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text